MANILA, Philippines, Nov. 11, 2024 /PRNewswire/ -- Start2 Group proudly launches the 2024 Philippines Startup Ecosystem Map at Philippine Startup Week, providing a visual snapshot of the nation's dynamic innovation landscape. This map highlights logos of the top 100 startups, leading corporates, key enablers, investors, service providers, government bodies, and academic institutions, offering a clear overview of the main players shaping the future of the Philippine startup ecosystem.
A Simple Way to See the Bigger Picture
The 2024 Philippines Startup Ecosystem Map provides an easy way to understand the landscape of innovation in the country. For startups, it serves as a tool to gain visibility and discover potential partners. For corporates and investors, it identifies new opportunities for collaboration and investment. Government agencies and public sector leaders can use the map to pinpoint key players and support areas that drive economic growth and innovation.
Highlighting Potential in Climate, Sustainability, and Energy
This map highlights emerging sectors critical to the nation's growth agenda, such as Climate, Sustainability, and Energy—areas identified by Start2's Climate Tech Competence Center as essential for future progress. Though still developing, these sectors hold significant potential for innovation and investment, offering unique opportunities to support sustainable solutions that align with the Philippines' long-term vision. By visually mapping these underexplored areas, the resource connects stakeholders with startups and key players ready to drive transformative progress in these high-impact fields.
A 360° View of Innovation
The Philippines Startup Ecosystem Map provides a 360-degree view of the nation's innovation network, visually capturing the entire ecosystem in a single, circular design. Startups, investors, corporates, and enablers can quickly spot opportunities for new partnerships and collaborations. The map is a practical tool for building relationships and exploring new opportunities for growth and success in the dynamic Philippine startup community.
"Our mission is to connect startups with forward-thinking corporates and investors to drive meaningful change in the Philippines," says Claus Karthe, CEO and Founder of Start2 Group Asia. "With the Philippines Startup Ecosystem Map, we aim to inspire corporates to collaborate with startups, integrating startup-driven innovation into their products and processes to better serve their customers and build a more sustainable, innovative future."
Discover the Philippines Startup Ecosystem Map today at
https://start2.group/program/startup-ecosystem-map-ph/
About Start2 Group
Start2 Group is a global innovation leader taking your startup journey to the next level. As a premier startup ecosystem platform, Start2 Group serves as the ultimate destination for growth-oriented startups, corporations, investors, and public sector to shape and scale ventures with growth potential.
Founded in 2008, Start2 Group has consistently played a pivotal role in the success stories of thousands of startups, guiding them seamlessly from initial fundraising to global expansion. We operate in key markets across Europe, the Americas, Asia, and the Middle East, shaping the future of innovation on a global scale.
For more information, please contact:
Eileen Wong, Director of Marketing, Asia
Start2 Group
Eileen.Wong@start2.group
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Start2 Group unveils the 2024 Philippines Startup Ecosystem Map: A 360° View of Innovation and Opportunity
ALL-RISE Study Included Over 1,924 Patients in 59 Sites Across
North America, Asia, Europe and the Middle East
NEWPORT BEACH, Calif., Jan. 3, 2025 /PRNewswire/ -- CathWorks, a global leader in medical device digital health innovations, announced today the successful completion of enrollment of the Advancing Cath Lab Results with FFRangio Coronary Physiology Assessment (ALL-RISE) randomized controlled trial (RCT). This landmark study represents a significant milestone in the field of interventional cardiology, evaluating the clinical and economic benefits of the CathWorks FFRangio® System in diagnosing and treating coronary artery disease (CAD), offering potentially groundbreaking evidence that could redefine the standard of care.
The ALL-RISE Study included over 1,924 patients across 59 sites in North America, Asia, Europe and the Middle East. Participants presenting with coronary stenoses of intermediate significance and requiring physiology assessment were randomized to receive either FFRangio-guided treatment or invasive pressure wire-guided treatment. Notably, this was the first-ever randomized controlled trial in the United States to assess clinical outcomes using an angiography-based tool for physiologic lesion assessment.
In a joint statement, the ALL-RISE Study Chair, Dr. Ajay J. Kirtane (NewYork-Presbyterian/Columbia University Irving Medical Center) and Principal Investigators, Dr. William Fearon (Stanford University) and Dr. Allen Jeremias (St. Francis Hospital & Heart Center), stated, "On behalf of the study executive committee, we would like to congratulate and thank all the global investigators, study coordinators and patients who collectively enabled this incredible accomplishment. The high level of engagement and record speed of enrollment parallel the growing adoption of FFRangio globally. We look forward to sharing the results of this landmark study after clinical follow-up is completed."
CathWorks Sr. Director of Clinical Affairs, Alex Froimovich M.D., added, "The completion of ALL-RISE enrollment marks a significant milestone for our company and team's mission to transform how cardiovascular disease is diagnosed and treated. We believe this study, adding to FFRangio's growing body of clinical evidence, has the potential to significantly advance the field of coronary physiology and close the gap between its current adoption and the appropriate use guidelines recommendations. FFRangio has already demonstrated higher diagnostic accuracy over all other angio-based technologies, highlighting the fact that not all angio-based technologies are created equal, and therefore technology-specific clinical data are needed."
Cardiovascular disease (CVD) remains the leading cause of death in the United States. According to the American Heart Association's (AHA) 2024 Heart Disease and Stroke Statistics Update, CVD accounted for 931,578 deaths in the U.S. in 2021, and close to 18 million deaths globally. Coronary artery disease (CAD) is the single largest contributor, responsible for over 40% of CV deaths. CathWorks believes the results from the ALL-RISE study will build on what the company refers to as a new era in physiology, underscoring FFRangio as the new standard of care with the potential to drive better patient outcomes while delivering tangible economic and resource utilization benefits to healthcare systems.
ABOUT CATHWORKS
CathWorks is the leader in digital health innovations that can improve the lives of patients globally. The CathWorks FFRangio® System combines artificial intelligence and advanced computational science, transforming how cardiovascular disease is diagnosed and treated. The FFRangio System obtains physiologic information from routine angiograms, eliminating the need for drug stimulation and invasive pressure wires. It provides physicians with quick and reliable intraprocedural FFRangio values for the entire coronary tree. For more information on CathWorks, visit www.cath.works and follow @CathWorks on LinkedIn.
Investors:
Mike Feher
mike.feher@cath.works
Media:
Sarita Monico
sarita.monico@cath.works
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
CathWorks Announces the Completion of Enrollment for Landmark ALL-RISE Randomized Controlled Trial
